Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
This is too funny. 1,287,930 shares traded and it's back down to 0.105.
VANC Pharmaceuticals Announces Appointment of Mr. Bob Rai to its Board of Directors
VANCOUVER, BRITISH COLUMBIA--(Marketwired - June 5, 2015) - VANC Pharmaceuticals Inc. (TSX VENTURE:NPH)(OTCQB:NUVPF) ("VANC" or the "Company"), a pharmaceutical company focused on the Canadian generic drug and over-the-counter (the "OTC") markets, is pleased to announce that Mr.Bob Rai has been appointed to the Company's Board of Directors effective immediately. Mr. Rai is a pharmacist with over 15 years of experience and is partner in a chain of The Medicine Shoppe Pharmacy (www.pharmacybc.com).
"We are excited to have someone with Mr. Rai's industry experience, track record as an entrepreneur and global pedigree join our board. We welcome him to our growing team and eagerly await his input on the strategic direction of our Company," said Arun Nayyar, CEO of VANC. "As we begin the commercialization of our product portfolio it is crucial that our team be optimized and Mr. Rai's direct experience in the Canadian retail and institutional pharmacy business is going to be an immediate value add and impactful addition for the Company."
Mr. Rai is a graduate of the University of British Columbia with Bachelor of Science Degrees in Biochemistry and Pharmaceutical Science. In addition to operating a chain of The Medicine Shoppe Pharmacies in Greater Vancouver for the past 15 years, he has had several successful entrepreneurial and charitable endeavors. In 1998 Mr. Rai and his partners pioneered and revolutionized the online pharmacy business to the United States. The online sales and distribution of prescription medicines saw unprecedented industry growth and as other operators followed suit, the unique business concept became a billion dollar industry across Canada.
Mr. Rai is also Chairman and CEO of Canada Pacific Global Pharmaceuticals and Chairman of its subsidiary, PharmaCanada Inc. (www.earlycancerdetect.com). He has served as President of the Philippines Canada Trade Council (PCTC) from 2006-2007 and held the position of Vice-President from 2004-2006. As President of PCTC, he led a successful Trade Mission to Manila with endorsements from His Excellency Canadian Prime Minister Stephen Harper, Honorable Premier Gordon Campbell of British Columbia and Minister of International Trade and Industry of Canada David Emerson.
In 2013 Mr. Rai was the recipient of the Queen's Diamond Jubilee Medal for his over 18 years of community and volunteer work. His charitable and community volunteer activities include: Alumni UBC Advisory Council representing the Faculty of Pharmaceutical Science, Director of Tapestry Foundation for Health Care, Rotary Club of Vancouver Fraserview and cabinet member of "A Night of Miracles" for BC Children's Hospital.
"I am impressed with how far VANC has come as a startup in a highly competitive industry and commend the existing team for building a product portfolio, registering it with Health Canada and rolling it out commercially in such a cost and time efficient manner. I look forward to working with the team and helping them with governance, technology, product acquisition and accelerating sales," said Mr. Bob Rai.
The Company has also set aside 400,000 incentive stock options at $0.45 for a period of five years and 800,000 incentive stock options at $0.55 for a period of two years to Directors, Officers and Consultants.
On behalf of:
VANC Pharmaceuticals Inc.
Arun Nayar, President & CEO
Cautionary Note Regarding Forward-looking Statements: Information in this press release that involves VANC's expectations, plans, intentions or strategies regarding the future are forward-looking statements that are not facts and involve a number of risks and uncertainties. VANC generally uses words such as "outlook," "will," "could," "would," "might," "remains," "to be," "plans," "believes," "may," "expects," "intends," "anticipates," "estimate," "future," "plan," "positioned," "potential," "project," "remain," "scheduled," "set to," "subject to," "upcoming," and similar expressions to help identify forward-looking statements. The forward-looking statements in this release are based upon information available to VANC as of the date of this release, and VANC assumes no obligation to update any such forward-looking statements. Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of VANC and are subject to risks, uncertainties and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
VANC Pharmaceuticals Inc.
Arun Nayar
President & CEO
anayar@vancpharm.com
Investor Relations:
Kam Thindal
+ 1 (604) 566-9233
kam@htcapitalcorp.com
Read more: http://www.digitaljournal.com/pr/2575920#ixzz3cCNuUdVv
Yes, so you keep telling us. Do you have any facts to back up any of these statements?
What I have always found amazing is how many oil & gas "Tycoons" there are commenting on this sub penny stock. You'd think they would have better thing to do with their time and money. ;)
Yes if makingmoneynow (of Stockhouse fame) knows of what he speaks, this stock could be a serious money maker. Could make up my deficit and then some. Just not sure I'm ready to add yet; although I'm contemplating it.
Yes I am still following, as I still have a lot of shares from the Alda days when Owen ran it into the ground. Here's hoping I can finally make some money with what I have left. Not selling until I am in the green or it blows up; but I must say it does sound much more promising this time.
First of all, it hasn't been in penny land for 5 years. Second, it has 4.33 Billion shares. This sub-penny is on life support.
Cytosorbents Corp (NASDAQ:CTSO) Director Al Kraus unloaded 100,000 shares of the stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $0.27, for a total value of $27,000.00. Following the sale, the director now directly owns 1,393,631 shares of the company’s stock, valued at approximately $376,280. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Shares of Cytosorbents Corp (NASDAQ:CTSO) opened at 0.27 on Thursday. Cytosorbents Corp has a one year low of $0.09 and a one year high of $0.35. The stock has a 50-day moving average of $0.25 and a 200-day moving average of $0.24. The company’s market cap is $80.7 million.
Cytosorbents Corp (NASDAQ:CTSO) last announced its earnings results on Tuesday, August 12th. The company reported ($0.01) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.01). Analysts expect that Cytosorbents Corp will post $-0.03 EPS for the current fiscal year.
Separately, analysts at HC Wainwright initiated coverage on shares of Cytosorbents Corp in a research note on Monday. They set a “buy” rating and a $1.00 price target on the stock.
CytoSorbents Corporation is a development stage critical care focused company using blood purification to treat life-threatening illnesses.
BuyMyAsk: Good post and wise words to trade by, which is why a sold what I did in this latest run-up. I will probably re-buy what I sold as well. When that will be I'm not sure. Right now it is a hold with what I have left and a wait and see as to when I re-buy what I sold. As BMA says weigh all of the info you have before you decide what is best for you.
When you have volume like we just had the day trading penny flippers move in and then move out; which makes your decision that much harder and skews your perspective on the stock. Have a good day all.
No you are not posting in vain. I for one read them; but I also read the Northern Ontario Business paper at home; so I am very well educated on the Ring of Fire companies. I am invested in KWG, as well as a couple of others; and have been in and out of others as well over the years. Made big bucks when Noront shot up to the moon. Here's hoping that KWG does better than Spider Resources did when they got bought out for not near what it was worth a few years ago. So keep it up, as you are not alone here.
New Web Site: http://www.nuvapharm.com
iCo Therapeutics Inc. Announces Overnight Marketed Equity Offering
52 minutes ago - ACQUIREMEDIA
VANCOUVER, Jan. 21, 2014 /PRNewswire/ - iCo Therapeutics Inc. ("iCo" or the "Company") (TSXV: ICO) (OTCQX: ICOTF) announced today that it has undertaken an overnight marketed public offering (the "Offering") of units (the "Units"), comprised of common shares of the Company and common share purchase warrants (a "Warrant"). The Offering is to be effected in each of the provinces of British Columbia, Alberta and Ontario by way of a prospectus supplement to iCo's base shelf prospectus dated July 3, 2012 and elsewhere on a private placement basis. Prior to the Offering, iCo had 67,811,230 common shares issued and outstanding. The number of Units to be distributed under the Offering, the price of each Unit and the exercise price of each Warrant will be determined in the context of the market.
The Company expects to close the Offering during the week of January 27, 2014, subject to satisfaction of customary closing conditions, including, but not limited to, the receipt of all necessary regulatory and stock exchange approvals, such as the final approval of the TSX Venture Exchange.
The securities described herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities laws, and accordingly, may not be offered or sold to, or for the account or benefit of, persons in the United States or "U.S. persons," as such term is defined in Regulation S promulgated under the U.S. Securities Act ("U.S. Persons"), except in compliance with the registration requirements of the U.S. Securities Act and applicable state securities requirements or pursuant to exemptions therefrom. This press release does not constitute an offer to sell or a solicitation of an offer to buy any of the Company's securities to, or for the account of benefit of, persons in the United States or U.S. Persons.
About iCo Therapeutics
iCo Therapeutics in-licenses and redefines existing drug candidates or generics by employing reformulation and delivery technologies for new or expanded use indications. The Company has exclusive worldwide rights to two drug candidates - iCo-007 for Diabetic Macular Edema (DME) and iCo-008 for other sight-threatening diseases. iCo-007 is in Phase 2 clinical studies for DME. With Phase 2 clinical history, iCo-008 is targeted for the treatment of keratoconjunctivitis and wet age-related macular degeneration. In addition, iCo holds worldwide rights to an oral drug delivery platform. The first platform candidate is the Oral Amp B Delivery system, utilizing a known anti-fungal drug to treat life-threatening infectious diseases. iCo trades on the TSX Venture Exchange under the symbol "ICO" and the OTCQX under the symbol "ICOTF". For more information, visit the Company website at: www.icotherapeutics.com.
No regulatory authority has approved or disapproved the content of this release. Neither the TSX Venture Exchange nor its Regulatory Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward Looking Statements
Certain statements included in this press release may be considered forward-looking statements" within the meaning of applicable securities laws. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will," and similar references to future periods and includes, but is not limited to, statements about the timing of the closing of the Offering, the satisfaction and timing of the receipt of required regulatory approvals and other conditions to closing of the Offering and the jurisdictions in which the Units will be offered. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on iCo's current beliefs as well as assumptions made by and information currently available to iCo and relate to, among other things, anticipated financial performance, business prospects, strategies, regulatory developments, market acceptance and future commitments. Readers are cautioned not to place undue reliance on these forward-looking statements, which are based only on information currently available to iCo and speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by iCo in its public securities filings and on its website, actual events may differ materially from current expectations. iCo disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
SOURCE iCo Therapeutics Inc.
You are right. It does not add up. Now having said that I still check this board out every now and again, as SIOR was a great flipper for me. I bought it as a flipper and always treated it as a flipper. Made a lot of money in the process and was very lucky to get out shortly before the delisting. Bull.... luck really; but you have to have a little luck when trading these pennies. Therefore, in conclusion, I really hope that this Screaming Eagle person is correct and they relist, as I would love to have the opportunity to flip this again at some point. In the mean time, good luck to all those that were caught in the delisting.
2.5 billion shares and the decimated share price over the years should tell you all you need to know about this stock. I took my lumps a long time ago. Do not be fooled. The pumpers here just want your hard-earned money.
Alda Pharmaceuticals director McCoy resigns
2012-12-05 16:12 ET - News Release
Dr. Terrance Owen reports
DR. MCCOY RESIGNS AS A DIRECTOR AND JOINS ALDA'S ADVISORY BOARD
Alda Pharmaceuticals Corp. director Dr. William McCoy has resigned, effective Nov. 28, 2012, and has joined the company's advisory board.
In 2005, Dr. McCoy became a director of Alda and chief technology officer of Phigenics LLC, a life sciences technology company based in Chicago, Ill. In 2001, he received the Intellectual Property Law Association inventor of the year award, and a medal for outstanding contribution to management and science from the International Water Association in Berlin. He has served the American Society of Heating, Refrigerating and Air-conditioning Engineers (ASHRAE) as chair of the environmental health committee, and is presently chair of the committee developing a new standard: preventing legionellosis associated with building water systems. Dr. McCoy authored a full-length book, "Preventing Legionellosis," in 2006, and holds 29 patents in diagnostics, control and manufacturing of anti-microbials. Dr. McCoy's expertise in infection control will be an important asset to the company as it continues the development of its T36 technology.
The company wishes to thank Dr. McCoy for his service as a director and welcomes him to the advisory board. He joins Dr. Brian Conway, who is an internationally recognized researcher in the field of infectious diseases. The company is expecting to appoint additional equally qualified individuals to its advisory board to reflect its focus on the acquisition of the global marketing and sales rights to novel generic, over-the-counter and natural pharmaceutical products.
The company currently has a vacancy on its board of directors and is seeking a qualified person who can contribute to this new international pharmaceutical marketing effort.
We seek Safe Harbor.
Alda Pharmaceuticals arranges $1-million financing
2012-12-03 18:46 ET - News Release
Mr. Terrance Owen reports
NON BROKERED PRIVATE PLACEMENT FINANCING
Alda Pharmaceuticals Corp. has arranged a non-brokered private placement of up to 10 million units at a price of 10 cents per unit for gross proceeds of up to $1-million.
Each unit will consist of one common share of the company and one share purchase warrant. Each warrant entitles the holder to purchase one additional common share of the company for a period of 24 months at a price of 20 cents per common share.
Any finder's fee will be paid by the company in accordance with the policies of the TSX Venture Exchange.
Proceeds from the offering will be used by Alda for general corporate and working capital purposes.
The above private placement is subject to all regulatory and board approvals.
Alda appoints Beukman, Kennedy directors
2012-11-15 18:04 ET - News Release
Mr. Terrance Owen reports
NEW DIRECTORS JOIN THE BOARD OF ALDA
Eugene Beukman and Tom Kennedy have joined the board of directors of Alda Pharmaceuticals Corp., effective immediately.
Mr. Beukman is the corporate counsel of the Pender group of companies, a position he has held since January, 1994. He graduated from the Rand University of Johannesburg, South Africa, with a bachelor of law degree and a bachelor of law honours postgraduate degree in 1987. He has over 30 years experience in the acquisition of assets and joint ventures. He is president and director of a number of publically traded companies on the TSX Venture Exchange.
Mr. Kennedy is a graduate of the University of British Columbia, having received his bachelor of commerce and business administration degree in 1973 and his juris doctor degree in 1974. Mr. Kennedy was admitted to the B.C. bar in 1975 and has practised law for 36 years. After seven years of employment with the Canadian Federal Department of Justice, Mr. Kennedy has primarily focused as a legal, financial and business consultant to publicly traded companies. Mr. Kennedy is currently a member of the Law Society of British Columbia, the Canadian Bar Association and the British Columbia Bar Association and an associate member of the American Bar Association. Mr. Kennedy currently serves in positions as chief executive officer, president, vice-president and secretary of several TSX Venture Exchange and Canadian National Stock Exchange publicly traded companies, primarily focused on mineral exploration.
Mr. Beukman and Mr. Kennedy replace Dr. Ronald Zokol and Dr. Linda Allison, who have served as directors since 2003 and have resigned from the board as of Nov. 13, 2012. The company wishes to express its gratitude to Dr. Zokol and Dr. Allison for their long service as directors and wishes them well in their future endeavours.
We seek Safe Harbor.
What oil ventures?
Sorry Janet, nothing personal about your picks. I hope they work out very well for you; but I am done with these sub pennies. I still hold BCND just in case, CTSO and SIOR because I still think they have potential in their respective fields, TUCA because your guess is as good as mine, VTSI because I made money once and they really have a good product if you are into guns, which I am not, but is irrelevant. The rest I made a couple of bucks and sold or they tanked and I lost my investment. Think the crooks behind GARB and LFBG. Anyway I'm slowly working my way out and into TSX and TSX Venture stocks only. I still check in now and again on your site just to hear what is going on. Whatever happened to Surf by the way? Anyway, be happy and be safe. As Cat Stevens once said it's a "Wild World". :)
I feel for you. I made the rare mistake of being caught up in the hype of the early days as well; so I hope you get your wish, as it would benefit many. I do not know if it is possible, but I think the only way that happens is if this shell is taken over by an honest group and something else is done with it.
Just passing through and wondering why people are still posting on here concerning the fact that this company was a fraud. I believe the proof was disclosed a long time ago. Why waste your time beating a dead horse?
I'm sure you meant all of "us" to the cleaners! :)
I for one am over being disgruntled. I took my loss and have recently sold this dog. I only have a few more American pennies to unload and then a few R/S Venture pennies and I’m done with these types of investments. I have learnt my lesson, mostly the hard way. I have several higher end Ventures and TSX stocks and that is where my investment money stays from now on. The most important lesson I have learnt is to never hold a stock very long ever again. No longer a good strategy in these crooked markets. Not necessarily day trading, as I don’t care for the practice; but buy low and sell high within a very short time frame. Good luck to all in Penny Land! :)
Dr. Owen:
I have to say that you are doing a fantastic job at growing the company since the consolidation. We are all extremely impressed with your ability to operate a company in such an exemplary manner. Bravo and keep up the great work. We are all looking forward to hearing about all of the wonderful new ideas coming down the pipeline. Good day to you sir and may life bring you nothing but happiness and good health.
*******
__________________________________________________________________
Do I sense a hint of sarcasm in your message?
Progress has not been as rapid as I had hoped. If you were in my shoes, you would see that much of what needs to be done in public companies is laying ground work and waiting. It is frustrating but comes with the territory.
Regards,
Terry Owen
DARPA Awards $3.8 Million Contract to CytoSorbents Corporation
1 hour ago - ACQUIREMEDIA
MONMOUTH JUNCTION, NJ -- (Marketwire) -- 08/06/12 -- CytoSorbents Corporation (OTCBB: CTSO), a pioneer in the use of blood purification to treat life-threatening illnesses such as sepsis, trauma, burn injury, lung injury and pancreatitis, announced that the Defense Advanced Research Projects Agency, or DARPA, has awarded the Company a technology development contract worth up to $3.8 million as part of its Dialysis-Like Therapeutics (DLT) program to treat sepsis, pending satisfactory achievement of key milestones. Sepsis is characterized by an overzealous immune response to a serious infection that leads to severe inflammation, organ failure and death in many cases. Sepsis is one of the leading causes of death in the world, killing millions of people each year and costing tens of billions of dollars to treat.
DARPA, the U.S. Department of Defense agency responsible for funding cutting-edge programs such as the internet, the global positioning satellite system (GPS), and robotic surgery, is funding the development of a portable, artificially intelligent blood purification system that can detect and remove, in real time, substances that can contribute to sepsis, including cytokines, toxins, biowarfare agents, pathogens, and activated cells. The goal is to save the lives of injured warfighters and civilians afflicted with sepsis, where approximately one in every three patients die today, even with the best medical treatment.
Under the terms of this contract, CytoSorbents will develop next-generation broad-spectrum, porous polymers capable of removing cytokines, toxins and certain biowarfare agents from whole blood, with $1.5 million in funding designated for the first of five years, based upon the achievement of pre-determined milestones.
Dr. Phillip Chan, Chief Executive Officer, stated, "We are delighted to officially begin working with DARPA on this exciting project and are honored to have had our unique core blood purification technology selected for funding. We are one of the industry leaders in the area of blood purification to treat sepsis and other critical care illnesses, with our first-in-class CytoSorb® cytokine filter currently approved and commercialized in the European Union. That being said, under this DARPA program, we are looking to significantly advance our polymer technologies to not only remove cytokines, but also a wide variety of toxins, and do so with little to no anti-coagulation in both high flow and microfluidic systems. The excessive production of cytokines, or 'cytokine storm,' is common in the worst forms of sepsis, and triggers massive inflammation that can lead to organ failure and infection -- the two leading causes of death in the ICU. Meanwhile, toxins produced by bacteria, viruses and other pathogens play an additional devastating role on the body, poisoning or killing cells, leading to widespread tissue destruction and worsened inflammation and sepsis. And the threat of a biowarfare attack with toxins such as ricin and botulinum remains a perennial concern. Our porous polymers are ideally suited to achieve the broad spectrum removal that is needed to counter most of these agents."
Dr. Chan continued, "Because of the maturity of our technology, we are confident in our ability to meet DARPA's timetable for technology development and strict performance metrics. Over the past several months, we have also collaborated with some of the leading potential systems integrators, to include our technologies into their integration proposals, under a separately funded DARPA DLT solicitation. The role of the systems integrator is to put together the best detection, separation and predictive modeling technologies into a single blood purification system and guide it to human clinical trials within 4 to 5 years. These partnerships are mutually beneficial and will help to contribute to the success of the overall program."
Dr. Chan concluded, "Just within the recent past, we have seen many high-profile cases of sepsis here in the U.S. including a young woman injured from a fall from a broken homemade zip-line who developed sepsis from a 'flesh-eating' bacterial infection, and a 12-year-old boy who died of unrecognized sepsis after cutting his arm during a basketball game. Unfortunately, these cases are not unusual, with thousands of patients dying silently from sepsis every day in hospitals around the world. The number of sepsis cases in the U.S. alone has doubled in the past decade, and continues to climb due to increased antibiotic resistance, a high rate of hospital-acquired infections, and an aging baby boomer population that is prone to infection due to age, diseases such as diabetes and cancer, and the use of implantable medical devices such as artificial hips and knees. There are currently no approved therapies to treat sepsis in the U.S. or in the European Union. Therapies like CytoSorb® and the device being proposed by DARPA are sorely needed and we are proud to be part of this worthy effort."
This material is based upon work supported by DARPA and SSC Pacific under Contract No. N66001-12-C-4199. Any opinions, findings and conclusions or recommendations expressed in this material are those of the author(s) and do not necessarily reflect the views of DARPA and SSC Pacific.
About CytoSorbents, CytoSorb®, and HemoDefend
CytoSorbents Corporation is a critical care focused therapeutic device company using blood purification to modulate the immune system and fight multi-organ failure in life-threatening illnesses. Its purification technology is based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and adsorption. In 2011, CytoSorb®, the Company's flagship product, achieved European regulatory approval as an extracorporeal cytokine filter, and can now be sold throughout the European Union (E.U.) under the CE Mark to be used in clinical situations where cytokines are elevated. The goal of CytoSorb® is to modulate the immune system by reducing "cytokine storm" in critically ill patients that could otherwise lead to deadly inflammation, multiple organ failure, immune dysfunction, and often death in common illnesses such as sepsis, trauma, burn injury, acute respiratory distress syndrome, and pancreatitis. CytoSorb® has demonstrated statistically significant reductions in mortality in septic patients at high risk of death in early studies and is now being sold in Germany for the treatment of critical care illnesses, with availability in other E.U. countries planned in the future, assuming adequate and timely funding, and continued positive results from our clinical studies. HemoDefend is a development-stage blood purification technology platform for the blood transfusion industry intended to reduce transfusion reactions and safeguard the quality and safety of blood products. The HemoDefend technology utilizes the Company's polymer bead technology to remove many substances, such as antibodies, free hemoglobin and inflammatory mediators that can cause potentially serious and sometimes fatal transfusion reactions. CytoSorb® and HemoDefend are just two of a number of different polymers the Company has designed for various medical applications, including improved dialysis, reduction of post-surgical complications, the potential treatment of inflammatory and autoimmune disorders, rhabdomyolysis in trauma, drug detoxification, and others. Additional information is available for download on the Company's website: www.cytosorbents.com
Forward-Looking Statements
This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release are not promises or guarantees and are subject to risks and uncertainties that could cause our actual results to differ materially from those anticipated. These statements are based on management's current expectations and assumptions and are naturally subject to uncertainty and changes in circumstances. We caution you not to place undue reliance upon any such forward-looking statements. Actual results may differ materially from those expressed or implied by the statements herein. CytoSorbents Corporation and CytoSorbents, Inc believe that its primary risk factors include, but are not limited to: obtaining government approvals including required FDA and additional CE Mark approvals; ability to successfully develop commercial operations; dependence on key personnel; acceptance of the Company's medical devices in the marketplace; the outcome of pending and potential litigation; compliance with governmental regulations; reliance on research and testing facilities of various universities and institutions; the ability to obtain adequate and timely financing in the future when needed; product liability risks; limited manufacturing experience; limited marketing, sales and distribution experience; market acceptance of the Company's products; competition; unexpected changes in technologies and technological advances; and other factors detailed in the Company's Form 10-K filed with the SEC on March 30, 2012, which is available at http://www.sec.gov.
Image Available: http://www2.marketwire.com/mw/frame_mw?attachid=1985309
Contact:
CytoSorbents Corporation
Dr. Phillip Chan
Chief Executive Officer
(732) 329-8885 ext. *823
pchan@cytosorbents.com
Source: CytoSorbents Corporation
Good afternoon Janet. Already made money on SIOR once and got back in again awhile back. It is hard to make money anywhere these days, although I see another bull market for gold and silver stocks coming again soon. Market Vectors Junior Gold Miners ETF on the rise again. :) AUN is a good silver buy right now and AVR is a gold steal at the moment. Both in my humble opinion of course. :) Made money on both in the past and own both at the present time.
This is in answer to my latest correspondence with Dr Owen. I received the answer to my email on the same day, which was yesterday. It does not say much; but at least he always answers. Don't know if this company will ever get back on its feet again; but until Alda is a total bust, I will continue to check in to see if its heart is still beating.
"Of course you realize that I cannot disclose anything that is not already public information.
As you know, we have a Memorandum of Understanding with a private pharmaceutical company to acquire certain of their products. Further, ALDA is still in possession of its intellectual property for which a very detailed plan is presented in the MD&A, subject to financing, of course.
Beyond that, I am not at liberty to disclose any plans, as it would be a violation of securities laws to do so.
Further, as our plans are consummated, we can only disclose what is accomplished at the time regardless of how that may fit into a larger strategy that cannot be disclosed until that also unfolds. No matter what we do, someone will be displeased but what we are doing is, in our opinion, in the best interests of shareholders.
Shareholders who contemplate "action" may not realize that, rather than keeping ALDA moving forward as a pharmaceutical company, we could have walked away and let it become an empty shell on the NEX which, at some time in the indeterminate future, may eventually have become a mining company. That alternative would have been a much longer wait than what we have pursued and I am aware of no "action" that has been successfully pursued against the principals of companies that have legitimately followed this course.
As always, I am working towards moving the company forward."
Regards,
Terry Owen
This is in answer to my latest correspondence with Dr Owen. I received the answer to my email on the same day, which was yesterday. It does not say much; but at least he always answers. Don't know if this company will ever get back on its feet again; but until Alda is a total bust, I will continue to check in to see if its heart is still beating.
"Of course you realize that I cannot disclose anything that is not already public information.
As you know, we have a Memorandum of Understanding with a private pharmaceutical company to acquire certain of their products. Further, ALDA is still in possession of its intellectual property for which a very detailed plan is presented in the MD&A, subject to financing, of course.
Beyond that, I am not at liberty to disclose any plans, as it would be a violation of securities laws to do so.
Further, as our plans are consummated, we can only disclose what is accomplished at the time regardless of how that may fit into a larger strategy that cannot be disclosed until that also unfolds. No matter what we do, someone will be displeased but what we are doing is, in our opinion, in the best interests of shareholders.
Shareholders who contemplate "action" may not realize that, rather than keeping ALDA moving forward as a pharmaceutical company, we could have walked away and let it become an empty shell on the NEX which, at some time in the indeterminate future, may eventually have become a mining company. That alternative would have been a much longer wait than what we have pursued and I am aware of no "action" that has been successfully pursued against the principals of companies that have legitimately followed this course.
As always, I am working towards moving the company forward."
Regards,
Terry Owen
Still can't trade the shares that I have... We can only wait and see if anything of significance materializes for now I guess. :)
Alda Pharmaceuticals reinstated for trading
2012-03-09 20:19 ET - Cease Trade Company Rescinded
Further to the TSX Venture Exchange bulletins dated Nov. 4, 2011, and March 7, 2012, the exchange has been advised that the cease trade order issued by the British Columbia Securities Commission on Nov. 4, 2011, has been revoked.
Effective at the opening Monday, March 12, 2012, trading will be reinstated in the securities of Alda Pharmaceuticals Corp. (Cusip 01407W 20 5).
Alda Pharmaceuticals reinstated for trading
2012-03-09 20:19 ET - Cease Trade Company Rescinded
Further to the TSX Venture Exchange bulletins dated Nov. 4, 2011, and March 7, 2012, the exchange has been advised that the cease trade order issued by the British Columbia Securities Commission on Nov. 4, 2011, has been revoked.
Effective at the opening Monday, March 12, 2012, trading will be reinstated in the securities of Alda Pharmaceuticals Corp. (Cusip 01407W 20 5).
ALDA PHARMACEUTICALS CORP. ("APH")
BULLETIN TYPE: Consolidation, Remain Suspended
BULLETIN DATE: March 7, 2012
TSX Venture Tier 2 Company
Pursuant to a special resolution passed by shareholders January 27, 2012, the Company has consolidated its capital on a 10 old for 1 new basis and has subsequently increased its authorized capital. The name of the Company has not been changed.
Effective at the opening, Thursday, March 8, 2012, the shares of ALDA Pharmaceuticals Corp. will be listed on TSX Venture Exchange on a consolidated basis; however, the shares of the Company will remain suspended from trading. The Company is classified as a 'Developing, manufacturing and selling infection control products' company.
Post - Consolidation
Capitalization: Unlimited shares with no par value of which
6,399,680 shares are issued and outstanding
Escrow: Nil shares are subject to escrow
Transfer Agent: Computershare Trust Company of Canada
Trading Symbol: APH (UNCHANGED)
CUSIP Number: 01407W 20 5 (new)
ALDA PHARMACEUTICALS CORP. ("APH")
BULLETIN TYPE: Consolidation, Remain Suspended
BULLETIN DATE: March 7, 2012
TSX Venture Tier 2 Company
Pursuant to a special resolution passed by shareholders January 27, 2012, the Company has consolidated its capital on a 10 old for 1 new basis and has subsequently increased its authorized capital. The name of the Company has not been changed.
Effective at the opening, Thursday, March 8, 2012, the shares of ALDA Pharmaceuticals Corp. will be listed on TSX Venture Exchange on a consolidated basis; however, the shares of the Company will remain suspended from trading. The Company is classified as a 'Developing, manufacturing and selling infection control products' company.
Post - Consolidation
Capitalization: Unlimited shares with no par value of which
6,399,680 shares are issued and outstanding
Escrow: Nil shares are subject to escrow
Transfer Agent: Computershare Trust Company of Canada
Trading Symbol: APH (UNCHANGED)
CUSIP Number: 01407W 20 5 (new)
Yes you are missing something. A Company posting info on a web site means absolutely nothing. They can post anything that they wish. Is it fact...? Not necessarily, although now you have a starting point to do your DD and find out if it is fact or fiction.
PRs are public relations reports and do not mean a lot. What people like to see are NRs which of course are news reports. This Company would benefit from a news report of any sort right about now. Will that be fact...? Again not necessarily; but it would be more believable. Bottom line, as a couple of others have reminded certain individuals, it's a Pinky and until it moves up and out of Pinky Land then you should trade it accordingly.
There has been so much negativity on this board lately that I do not see any technical analysis meaning much here at this time.
I rarely discuss my buys and sells on a site as it is meaningless and really should be perceived as a form of new investor manipulation.
Anyway, if you believe the leaders of this board then buy in at a price you like or can afford, hold/trade it and move on to bigger and better things for now. If you have any doubts, it’s simple, stay away or sell and move on to the aforementioned bigger and better things.
Happy trading to all this week.
No we are not; and neither are they if they still exist... Although they might have been fine if we had not found them...